Press Releases April 1, 2026 08:00 PM

Alerus Financial Corporation to Announce First Quarter Financial Results on Wednesday, April 29

Alerus Financial Corporation to report Q1 2026 financial results and host earnings call

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
ALRS

Alerus Financial Corporation announced that it will release its first quarter 2026 financial results on April 29, 2026, followed by a conference call for discussion and Q&A on April 30, 2026. The company is a commercial wealth bank and retirement services provider operating across multiple U.S. states.

Alerus Financial Corporation to Announce First Quarter Financial Results on Wednesday, April 29
ALRS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Alerus Financial Corporation will report Q1 2026 financial results on April 29, 2026.
  • A conference call for analysts and investors is scheduled on April 30, 2026, at 11:00 a.m. Central Time.
  • Alerus operates banking and wealth management offices in several states and provides retirement and benefit plans nationwide.

MINNEAPOLIS, April 02, 2026 (GLOBE NEWSWIRE) -- Alerus Financial Corporation (Nasdaq: ALRS) announced that it will issue its first quarter financial results on Wednesday, April 29, 2026.

Alerus Financial Corporation will also host a conference call at 11:00 a.m. Central Time on Thursday, April 30, 2026, to discuss its financial results. Analysts and institutional investors may participate in the question-and-answer session. Attendees are encouraged to register ahead of time for the call.

Conference Call Information
Date: Thursday, April 30, 2026
Time: 12:00 p.m. Eastern Time / 11:00 a.m. Central Time
Register: https://register-conf.media-server.com/register/BIff30a6d15e4e4b268617d2f78268fe7e

A recording of the call and transcript will be available at investors.alerus.com following the call.

About Alerus Financial Corporation
Alerus Financial Corporation (Nasdaq: ALRS) is a commercial wealth bank and national retirement services provider with corporate offices in Grand Forks, North Dakota, and the Minneapolis-St. Paul, Minnesota metropolitan area. Through its subsidiary, Alerus Financial, National Association, Alerus provides diversified and comprehensive financial solutions to business and consumer clients, including banking, wealth services, and retirement and benefit plans and services. Alerus provides clients with a primary point of contact to help fully understand their unique needs and delivery channel preferences. Clients are provided with competitive products, valuable insight, and sound advice supported by digital solutions designed to meet their needs. Alerus operates 26 banking and commercial wealth offices, with locations in Grand Forks and Fargo, North Dakota; the Minneapolis-St. Paul, Minnesota metropolitan area; Rochester, Minnesota; Southern Minnesota; Marshalltown, Iowa; Pewaukee, Wisconsin; and Phoenix and Scottsdale, Arizona. The Alerus Retirement and Benefit business serves advisors, brokers, employers, and plan participants across the United States.

Al Villalon, Chief Financial Officer
952-417-3733 (Office)
[email protected]
Investors.Alerus.com


Risks

  • The announcement does not provide guidance or preliminary results, creating uncertainty about the upcoming financial performance.
  • Market conditions and economic factors impacting the banking and retirement services sectors could affect the results.
  • Competition from other financial institutions and digital service providers in the banking and wealth management sectors presents ongoing challenges.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026